Clinical Response to Low-dose Omalizumab Treatment in Chronic Spontaneous Urticaria: A Retrospective Study of 179 Patients

Omalizumab is effective in chronic spontaneous urticaria unresponsive to antihistamines. Of the licensed dosing schedules, Korean patients prefer a low dose, of 150 mg/month, for financial reasons. However, real-world experiences of low-dose omalizumab consumption have not been reported. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: KIM, Min Jae, KIM, Bo Ri, KIM, Sae Hoon, CHANG, Yoon Seok, YOUN, Sang Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2023
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547060/
https://www.ncbi.nlm.nih.gov/pubmed/37646349
http://dx.doi.org/10.2340/actadv.v103.11627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547060/
https://www.ncbi.nlm.nih.gov/pubmed/37646349
http://dx.doi.org/10.2340/actadv.v103.11627

Ejemplares similares